trial

Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder

NCTId NCT00480571
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 90 (estimated)
Sponsored by BioLineRx, Ltd.
Primary completion 2007-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
90 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2007-06
Primary completion
2007-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
BL-1020BL 1020 High Dose

Sponsors

BioLineRx, Ltd.Lead Sponsor

Investigators

1
Michael Davidson, professorPrincipal Investigator

Sites

2 total
Tel Litwinsky, IsraelBucharest, Romania

Linked catalysts

1
Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizop — primary completion2007-12

Facts & assertions

4 sourced
Enrollment
90
Phase
PHASE2
Primary Completion Date
2007-12
Status
COMPLETED
relationships
The graph out of here
drug
BL-1020
drug
BL 1020 High Dose
drug
lead_sponsor
BioLineRx, Ltd.
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Michael Davidson, professor
person